Skip to content

Endometriosis interview series

Endometriosis interview series

March is Endometriosis Awareness Month, and Scailyte is proud to support this cause with the “Endometriosis interview series”

March is Endometriosis Awareness Month, and Scailyte is proud to support this cause with the “Endometriosis interview series”

We mark Endometriosis Awareness Month, and Scailyte is proud to support this cause with “The Endometriosis interview series”. We aim to highlight important aspects of Endometriosis directly from the top exponents! 

As a precision medicine company, Scailyte is dedicated to discovering clinically relevant biomarkers for diagnostics, prognostics, and treatment, starting from single-cell data sets in clinical data sets.

ScaiVision, our proprietary machine learning algorithm platform,  has been used for various biomarker discovery projects in collaboration with clinical, academic, and biotech partners, in different fields, including endometriosis.

We believe that precision medicine has the potential to transform the way endometriosis is diagnosed and treated, and we’re committed to driving progress in this field. Join us in celebrating Endometriosis Awareness Month and stay tuned for our upcoming interviews with leaders in the field.

About Scailyte

Scailyte is an ETH Zürich spin-off with a best-in-class artificial intelligence platform for the discovery of complex disease patterns from single-cell data. Our solution provides unprecedented insight into the disease and patients’ biology and enables the discovery of new clinically-relevant biomarker signatures by uncovering human’s hidden “single-cell” secrets. 

Scailyte’s proprietary best-in-class data analysis platform ScaiVision™ associates multimodal single-cell datasets (RNA-/TCR-/BCR-seq, proteomics, etc.) with clinical endpoints, such as disease diagnosis, progression, severity, treatment response, and toxicity response to identify ultra-sensitive biomarker signatures and cell functionality states. The performance and clinically-relevant applications of Scailyte’s platform ScaiVision have been demonstrated in well established CAR-T cell therapies and various clinical projects in Oncology and Immunology.

For more information, visit www.scailyte.com and connect on social media @LinkedIn and @Twitter.

ScailyteTM and ScaiVisionTM are registered trademarks proprietary to Scailyte AG.

Recent News

ISCT 2023

Diana Stoycheva and Filipa Teixeira will be attending the ISCT 2023 Annual Meeting from 31st May to ...

Read more

Recent News

Future Labs Live 2023

Scailyte will be attending the Future Labs Live event, taking place from 31st May to 2nd June 2023 a...

Read more

Recent News

The psychological and economic impact of endometriosis

We're thrilled to present the third episode of Scailyte's Endometriosis Awareness Series, where Cinz...

Read more

Recent News

Jan Lichtenberg joins Scailyte's Board of Directors

Scailyte, a biomarker discovery company leveraging single-cell omics and artificial intelligence, is...

Read more

Recent News

Challenges and opportunities for innovation in Endometriosis

Join us for the second episode of the Endometriosis Awareness Series on “Challenges and opportunit...

Read more

Recent News

Swiss Biotech Day 2023

Sarah Carl will be a panellist at the Swiss Biotech Association's Swiss Biotech Day 2023 on April 24...

Read more

Recent News

Deciphering Disease Mechanisms Through Functional Genomics

Tiwari lab studies gene-epigenetic interplay in cell identity & its disruption in cancer/neurologica...

Read more

Recent News

Women's Health Innovation Summit

Exciting news from Scailyte! We are thrilled to announce that we have been selected among the top 15...

Read more

Recent News

01 /04

ISCT 2023

Diana Stoycheva and Filipa Teixeira will be attending the ISCT 2023 Annual Meeting from 31st May to ...

Read more

Future Labs Live 2023

Scailyte will be attending the Future Labs Live event, taking place from 31st May to 2nd June 2023 a...

Read more

Recent News

02 /04

The psychological and economic impact of endometriosis

We're thrilled to present the third episode of Scailyte's Endometriosis Awareness Series, where Cinz...

Read more

Jan Lichtenberg joins Scailyte's Board of Directors

Scailyte, a biomarker discovery company leveraging single-cell omics and artificial intelligence, is...

Read more

Recent News

03 /04

Challenges and opportunities for innovation in Endometriosis

Join us for the second episode of the Endometriosis Awareness Series on “Challenges and opportunit...

Read more

Swiss Biotech Day 2023

Sarah Carl will be a panellist at the Swiss Biotech Association's Swiss Biotech Day 2023 on April 24...

Read more

Recent News

04 /04

Deciphering Disease Mechanisms Through Functional Genomics

Tiwari lab studies gene-epigenetic interplay in cell identity & its disruption in cancer/neurologica...

Read more

Women's Health Innovation Summit

Exciting news from Scailyte! We are thrilled to announce that we have been selected among the top 15...

Read more

Recent News